In addition, sgRad21-mediated B16-OVA tumor inhibition was abrogated by pretreatment of anti-CD8 depletion antibody, further suggesting that CD8+ T cells are required for the retarded tumor growth of sgRad21-expressing tumors (Figure 6C and Supplemental Figure 6B). This evidence concerns the gene CD8A and neoplasm.